EVOFEM BIOSCIENCES INC (EVFM) Stock Price, Forecast & Analysis
NASDAQ:EVFM • US30048L2034
EVFM Key Statistics, Chart & Performance
The current stock price of EVFM is 0.4782 USD. In the past month the price decreased by -58.42%. In the past year, price decreased by -95.52%.
EVFM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EVFM. When comparing the yearly performance of all stocks, EVFM is a bad performer in the overall market: 98.86% of all stocks are doing better.
EVFM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVFM. Both the profitability and financial health of EVFM have multiple concerns.
EVFM Financial Highlights
Over the last trailing twelve months EVFM reported a non-GAAP Earnings per Share(EPS) of -15.3. The EPS decreased by -553.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1676.29% | ||
| ROA | -552.28% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EVFM Forecast & Estimates
11 analysts have analysed EVFM and the average price target is 11.27 USD. This implies a price increase of 2256.96% is expected in the next year compared to the current price of 0.4782.
For the next year, analysts expect an EPS growth of 57.85% and a revenue growth 295.01% for EVFM
EVFM Ownership
EVFM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVFM
Company Profile
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
Company Info
EVOFEM BIOSCIENCES INC
12400 High Bluff Dr Ste 600
San Diego CALIFORNIA 92130 US
CEO: Saundra Pelletier
Employees: 119
Phone: 18585501900.0
EVOFEM BIOSCIENCES INC / EVFM FAQ
Can you describe the business of EVOFEM BIOSCIENCES INC?
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
What is the current price of EVFM stock?
The current stock price of EVFM is 0.4782 USD. The price decreased by -23.37% in the last trading session.
Does EVOFEM BIOSCIENCES INC pay dividends?
EVFM does not pay a dividend.
How is the ChartMill rating for EVOFEM BIOSCIENCES INC?
EVFM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of EVFM stock?
EVOFEM BIOSCIENCES INC (EVFM) has a market capitalization of 20.18M USD. This makes EVFM a Nano Cap stock.
When does EVOFEM BIOSCIENCES INC (EVFM) report earnings?
EVOFEM BIOSCIENCES INC (EVFM) will report earnings on 2022-11-14.
Can you provide the short interest for EVFM stock?
The outstanding short interest for EVOFEM BIOSCIENCES INC (EVFM) is 0.03% of its float.